Drug Profile

Resaeach programme : globular protein therapeutics - Guard Therapeutics

Latest Information Update: 28 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Guard Therapeutics
Class Anti-inflammatories; Antihyperglycaemics; Cardiovascular therapies; Recombinant proteins; Urologics
Mechanism of Action Alpha 1 microglobulin replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Preclinical Diabetes mellitus; Heart failure; Hereditary nephritis; Kidney disorders; Renal failure

28 Nov 2025 Guard therapeutics announces intention to submit IND application to regulatory body in January 2027
24 Sep 2025 Preclinical trials in Diabetes mellitus in Sweden (SC), prior to September 2025 (Guard Therapeutics pipeline, September 2025)
24 Sep 2025 Preclinical trials in Heart failure in Sweden (SC), prior to September 2025 (Guard Therapeutics pipeline, September 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com